Background: Bacterial resistance to antibiotics is one of the most serious challenge to global
public health. The introduction of new antibiotics in clinical settings, i.e. agents that belong to a new
class of antibacterials, act on new targets or has a novel mechanisms of action, may not be sufficient to
cope with the emergence of multidrug-resistant pathogens such as Staphylococcus aureus, Streptococcus
pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii and Escherichia
coli, which are increasingly prevalent in healthcare settings in Europe, the USA and Asia.
Hence, coordinated efforts in minimizing the risk of spread of resistant bacteria and renewing research
efforts in the search for novel antibacterial agents are urgently needed to manage this global crisis.
Objective: This review highlights the challenges and potential in using current technologies in the discovery
and development of novel antibacterial agents to keep up with the constantly evolving resistance
Conclusion: With the explosion of bacterial genomic data and rapid development of new sequencing
technologies, the understanding of bacterial pathogenesis and identification of novel antibiotic targets
have significantly improved.